-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-819 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-819 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-819 in B-Cell Acute Lymphocytic...
-
Product Insights
NewNet Present Value Model: Fate Therapeutics Inc’s FT-538
Empower your strategies with our Net Present Value Model: Fate Therapeutics Inc's FT-538 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Fate Therapeutics Inc’s FT-596
Empower your strategies with our Net Present Value Model: Fate Therapeutics Inc's FT-596 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Fate Therapeutics Inc’s FT-516
Empower your strategies with our Net Present Value Model: Fate Therapeutics Inc's FT-516 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Forma Therapeutics Inc’s FT-7051
Empower your strategies with our Net Present Value Model: Forma Therapeutics Inc's FT-7051 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Rebyota in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rebyota in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rebyota in Crohn's Disease (Regional Enteritis) Drug Details: Fecal microbiota,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMY-109 in Endometriosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMY-109 in Endometriosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMY-109 in Endometriosis Drug Details: AMY-109 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CGX-1321 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CGX-1321 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CGX-1321 in Pancreatic Cancer Drug Details: CGX-1321 is under development for the...
-
Analyst Opinions
Net Zero by 2050 – Industrial Decarbonization Gains Momentum (Vol.2)
Net Zero by 2050 Overview Businesses and tech giants globally are focusing on low-carbon products, renewables, and EVs to achieve net zero emissions. Key sectors such as aerospace, automotive, and technology are advancing sustainability through innovations in hydrogen, EVs, fuel cells, and smart energy solutions among others. The “Net Zero by 2050” report outlines decarbonization-related deals value and volume trends, VC investment activity and geographic trends, and leading investors. The report also provides facts and figures related to climate change,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-011 in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-011 in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-011 in Systemic Sclerosis (Scleroderma) Drug Details: FT-011 (SHP-627) is...